Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results.

The live audio webcast can be accessed via the Investor Relations section of the Company’s website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir’s website for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005905/en/

INVESTORS:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
[email protected]

MEDIA:
Michele Parisi
925-429-1850
[email protected]

Source: Cyteir Therapeutics

You May Also Be Interested In

• ROBAM Announces Breakthrough Dishwasher Technology, Poised to Lead in Industry
• Unlocking Creativity: Transfer Kingdom Introduces Revolutionary UV DTF Stickers
• Cox Media Group and DISH Reach A Multi-Year Deal and Restore Stations